Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:administeredBy |
intravenous injection
|
| gptkbp:alternativeName |
gptkb:AR-C69931MX
gptkb:cangrelor |
| gptkbp:approvedBy |
gptkb:United_States
percutaneous coronary intervention |
| gptkbp:ATCCode |
gptkb:B01AC10
|
| gptkbp:brand |
gptkb:Kengreal
gptkb:Kengrexal |
| gptkbp:CASNumber |
gptkb:163706-06-7
|
| gptkbp:compatibleWith |
prodrug
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:eliminationHalfLife |
3-6 minutes
|
| gptkbp:hasMolecularFormula |
gptkb:C17H25F3N5O12P3S
|
| https://www.w3.org/2000/01/rdf-schema#label |
AR-C
|
| gptkbp:inhibitedBy |
gptkb:P2Y12_receptor
|
| gptkbp:mechanismOfAction |
reversible P2Y12 inhibition
|
| gptkbp:metabolism |
dephosphorylation
|
| gptkbp:sideEffect |
bleeding
dyspnea |
| gptkbp:usedFor |
antiplatelet therapy
|
| gptkbp:bfsParent |
gptkb:Capital_Federal
gptkb:Буэнос-Айрес |
| gptkbp:bfsLayer |
5
|